ModifiedmhnPolicy CP.CPA.123

Desloratadine (Clarinex) and Desloratadine/Pseudoephedrine (Clarinex-D) prior authorization

Defines medical necessity and prior authorization criteria for desloratadine (Clarinex) and desloratadine/pseudoephedrine (Clarinex-D 12 Hour) for commercial lines of business; affects providers prescribing these agents and patients seeking coverage.

Policy Summary

Payermhn

PolicyDesloratadine (Clarinex) and Desloratadine/Pseudoephedrine (Clarinex-D) prior authorization

Policy CodePolicy CP.CPA.123

Change TypeRevised approval durationadded generic redirection

Effective Date08.01.18

Next Review Date

Key ActionPrior authorization required; document diagnosis, age, two antihistamine failures, use generic for brand requests, and limit dose per policy.

SourceLink

POLICY UPDATE CHANGES

Revised approval duration for Commercial line of business from length of benefit to 12 months or duration of request, whichever is less.

Revised policy/criteria section to also include generic desloratadine.

For brand requests, added redirection to generic.

Template changes applied to other diagnoses/indications and continued therapy section.

Commercialline of business

12 monthsapproval duration

2required antihistamine failures

5 mg/day

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

max desloratadine dose

redirectsbrand → generic

Coverage Criteria

Initial Approval Criteria

Covered when ALL of the following are met for Initial Approval (Allergic Rhinitis or Chronic Idiopathic Urticaria):

Initial Approval - Allergic Rhinitis/CIU: 1. Diagnosis of allergic rhinitis or chronic idiopathic urticaria; 2. Age: Clarinex ≥ 6 months OR Clarinex-D 12 Hour ≥ 12 years; 3. Failure of two oral antihistamines (e.g., cetirizine, loratadine) at up to maximally indicated doses unless contraindicated or intolerant; 4. If request is for brand Clarinex, member must use generic desloratadine unless contraindicated or experiencing clinically significant adverse effects; 5. Dose does not exceed: Clarinex 5 mg per day OR Clarinex-D 5 mg/240 mg per day.see nodes

Approval duration: 12 months or duration of request, whichever is less

Continuation Therapy Criteria

Covered when ALL of the following are met for Continued Therapy (Allergic Rhinitis or Chronic Idiopathic Urticaria):

Continued Therapy - Allergic Rhinitis/CIU: 1. Member meets one of the following: (a) currently receiving the medication via the Centene benefit or previously met initial approval criteria; or (b) continuity of care applies per state/product regulations; 2. Member is responding positively to therapy; 3. If request is for brand Clarinex, member must use generic desloratadine unless contraindicated or experiencing clinically significant adverse effects; 4. If request is for a dose increase, new dose does not exceed: Clarinex 5 mg per day OR Clarinex-D 5 mg/240 mg per day.see nodes

Approval duration: 12 months or duration of request, whichever is less

Other Indications / Label Changes

Other diagnoses/indications:

Other uses: 1. If the drug has undergone a label change within the last 6 months not yet reflected in this policy (e.g., new indication, age expansion, new dosing), follow the applicable policy for formulary status (for commercial: CP.CPA.190); 2. If the requested use (diagnosis, age, dosing) is not listed under section III (Diagnoses/Indications for which coverage is NOT authorized) and criterion 1 does not apply, refer to the off‑label use policy for the relevant line of business: CP.CPA.09 for commercial.

See referenced policies for handling recent label changes or off‑label requests

Non‑FDA approved indications that are not specifically addressed in this policy are excluded from coverage unless there is sufficient documentation of efficacy and safety in accordance with the plan’s off‑label use policy (CP.CPA.09) or applicable evidence‑of‑coverage documents. Requests for uses outside the FDA‑approved labeling should include supporting clinical information per the off‑label policy to be considered for authorization.

This clinical policy is a guide to medical necessity and is not medical advice or a directive for how to practice medicine. Providers retain responsibility for all clinical decisions and the medical care of their patients; the policy does not replace professional judgment or the provider–patient relationship.

Coding & Dosing

Age limits — Product-specific

Clarinex (desloratadine)Approved age: 6 months and older for perennial allergic rhinitis and chronic idiopathic urticaria; seasonal allergic rhinitis indication from age 2 years—policy age limit stated as ≥ 6 months for Clarinex

Clarinex‑D 12 Hour (desloratadine/pseudoephedrine)Approved age: 12 years and older for seasonal allergic rhinitis with nasal congestion

Age nuance for seasonal allergic rhinitisClarinex seasonal allergic rhinitis indication begins at 2 years of age per FDA language; policy consolidates age limits with Clarinex ≥ 6 months for relevant indications

Maximum doses — Product-specific

Clarinex (desloratadine) maximum daily dose5 mg per day for patients aged ≥ 12 years

Clarinex dosing by pediatric age

Provider Actions & Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for desloratadine (Clarinex) and desloratadine/pseudoephedrine (Clarinex‑D 12 Hour). Approval is granted when required clinical criteria are met, including diagnosis, age limits, dose limits, and documented prior antihistamine therapy failures.

Affected products: Clarinex (desloratadine) and Clarinex‑D 12 Hour (desloratadine/pseudoephedrine).
Approval requires meeting policy clinical criteria (diagnosis, age, dosing limits, prior therapy failures).

Step Therapy

Step Therapy — Antihistamine Failures Required

For initial approval, members must have failed two oral antihistamines (for example, cetirizine or loratadine) at up to maximally indicated doses unless they experienced clinically significant adverse effects or all are contraindicated.

Examples include cetirizine, loratadine, fexofenadine per Appendix B therapeutic alternatives.
Failures must be documented in the submitted clinical record.

Background

Desloratadine is a selective H1‑receptor antagonist indicated for relief of symptoms associated with seasonal and perennial allergic rhinitis and for chronic idiopathic urticaria. Formulations include Clarinex (desloratadine) and the combination product Clarinex‑D 12 Hour (desloratadine/pseudoephedrine), the latter providing an added oral decongestant for nasal congestion and indicated for seasonal allergic rhinitis in patients 12 years and older. Per the dosing guidance in this policy, the maximum recommended daily dose is Clarinex 5 mg/day (for age ≥12) and Clarinex‑D 5 mg/240 mg per day; FDA age indications and dosing vary by product and indication.

Definitions

Clarinex‑D 12 Hour — Indication

IndicationClarinex‑D 12 Hour (desloratadine/pseudoephedrine) is indicated for relief of nasal and non‑nasal symptoms of seasonal allergic rhinitis, including nasal congestion

Age for useApproved for adults and adolescents 12 years of age and older

Combination componentsContains desloratadine (H1 antagonist) plus pseudoephedrine (decongestant) for nasal congestion

Clinical policy — Definition / scope

Purpose of clinical policyProvides a guide to medical necessity to assist coverage decisions and benefit administration; not a contract or guarantee of payment

Not medical adviceThis clinical policy does not constitute medical advice, medical treatment, or a recommendation for treatment; providers must exercise professional medical judgment

Policy Summary

Payermhn

PolicyDesloratadine (Clarinex) and Desloratadine/Pseudoephedrine (Clarinex-D) prior authorization

Policy CodePolicy CP.CPA.123

Change TypeRevised approval durationadded generic redirection

Effective Date08.01.18

Next Review Date

Key ActionPrior authorization required; document diagnosis, age, two antihistamine failures, use generic for brand requests, and limit dose per policy.

SourceLink

On This Page

6–11 years: 2.5 mg/day; 1–5 years: 1.25 mg/day; 6–11 months: 1 mg/day

Clarinex‑D 12 Hour maximum daily dose5 mg desloratadine / 240 mg pseudoephedrine per day (per policy: 5 mg/day desloratadine component)

Documentation Required

Required Documentation

Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that the member has met all approval criteria. Documentation should include evidence of the two antihistamine failures and any contraindications or adverse events that preclude use of alternatives.

Include dates, doses, and response or adverse effects for prior antihistamine trials.
Attach relevant progress notes or test results to the prior authorization request.

Denial Risk

Non‑FDA Indications May Be Denied

Requests for non‑FDA approved indications that are not addressed in this policy are not authorized unless sufficient documentation of efficacy and safety is provided per the off‑label use policy CP.CPA.09 (for commercial) or evidence of coverage documents.

Non‑covered/off‑label use requires robust supporting literature and rationale per off‑label policy.
Absent sufficient evidence, requests will be denied as not authorized.

Documentation Required

Commercial Approval Duration — Documentation Required

Commercial approvals are granted for a maximum duration of 12 months or the duration of the request, whichever is less. Providers should document the requested approval duration on the prior authorization and ensure it does not exceed the Commercial limit.

Approval duration: up to 12 months or requested duration (whichever is less).
Providers must indicate desired duration on the request and include supporting rationale if shorter duration is requested.

Billing Rule

Brand‑to‑Generic Redirection

Brand product requests (e.g., Clarinex) may be redirected to generic desloratadine. Coverage of brand products requires documentation that generic alternatives are contraindicated or have caused clinically significant adverse effects.

If generic desloratadine is available, members must use generic unless contraindicated.
3Q 2025 update: brand requests may be actively redirected to generic; failure to request generic may affect coverage.

Development basisDeveloped from peer‑reviewed literature, guidelines, FDA status, expert input, and other clinical information